|
Viracta Therapeutics, Inc. (Virx) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Viracta Therapeutics, Inc. (VIRX) Bundle
Mit unserem (Virx) DCF-Taschenrechner, der für die Genauigkeit entwickelt wurde, können Sie die Bewertung von Viracta Therapeutics, Inc. unter Verwendung realer Finanzdaten bewerten und bieten vollständige Flexibilität, um alle wesentlichen Parameter für erweiterte Projektionen zu ändern.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.1 | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | -94.21 | -100 | 0 | 0 | -48.55 | -48.55 | -48.55 | -48.55 | -48.55 |
| EBITDA | -22.8 | -18.8 | -114.1 | -48.4 | -46.9 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | -1100.63 | -15640.83 | 100 | 100 | 100 | 20 | 20 | 20 | 20 | 20 |
| Depreciation | .0 | .0 | .2 | .2 | .5 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 0.15123 | 26.67 | 100 | 100 | 100 | 65.36 | 65.36 | 65.36 | 65.36 | 65.36 |
| EBIT | -22.8 | -18.8 | -114.3 | -48.6 | -47.4 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | -1100.78 | -15667.5 | 100 | 100 | 100 | 20 | 20 | 20 | 20 | 20 |
| Total Cash | 34.6 | 47.1 | 103.6 | 91.0 | 53.7 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .3 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 0 | 0 | 100 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
| Inventories | .0 | .0 | .0 | -.9 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0 | 100 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
| Accounts Payable | .8 | 1.6 | 2.9 | 2.5 | 2.4 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 38.16 | 1297.5 | 100 | 100 | 100 | 87.63 | 87.63 | 87.63 | 87.63 | 87.63 |
| Capital Expenditure | .0 | -.1 | -4.3 | .0 | -.1 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 0 | -45.83 | 100 | 100 | 100 | -9.17 | -9.17 | -9.17 | -9.17 | -9.17 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -22.8 | -19.0 | -202.2 | -49.2 | -47.4 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -22.0 | -18.2 | -204.9 | -48.5 | -48.3 | -2.2 | .0 | .0 | .0 | .0 |
| WACC, % | 14.17 | 14.17 | 14.17 | 14.17 | 14.17 | 14.17 | 14.17 | 14.17 | 14.17 | 14.17 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -2 | |||||||||
| Net Debt | 13 | |||||||||
| Equity Value | -15 | |||||||||
| Diluted Shares Outstanding, MM | 39 | |||||||||
| Equity Value Per Share | -0.39 |
What You Will Get
- Pre-Filled Financial Model: Viracta Therapeutics' actual data enables precise DCF valuation.
- Full Forecast Control: Adjust revenue growth, margins, WACC, and other key drivers.
- Instant Calculations: Automatic updates ensure you see results as you make changes.
- Investor-Ready Template: A refined Excel file designed for professional-grade valuation.
- Customizable and Reusable: Tailored for flexibility, allowing repeated use for detailed forecasts.
Key Features
- Comprehensive Data: Viracta Therapeutics’ historical financial statements and pre-filled projections.
- Customizable Variables: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: View Viracta Therapeutics’ intrinsic value update instantly.
- Intuitive Visuals: Dashboard graphs illustrate valuation outcomes and essential metrics.
- Engineered for Precision: A specialized tool designed for analysts, investors, and finance professionals.
How It Works
- Download the Template: Gain immediate access to the Excel-based VIRX DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model automatically recalculates Viracta Therapeutics’ intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the results to inform your investment or financial analysis.
Why Choose Viracta Therapeutics Calculator?
- Accuracy: Utilizes real Viracta Therapeutics financials for precise data.
- Flexibility: Allows users to easily adjust and experiment with inputs.
- Time-Saving: Eliminate the need to create a financial model from the ground up.
- Professional-Grade: Crafted with the expertise and usability expected at the CFO level.
- User-Friendly: Simple to navigate, even for those lacking advanced financial modeling skills.
Who Should Use This Product?
- Biotech Students: Explore drug development processes and apply them using real-world data.
- Researchers: Integrate cutting-edge therapeutic models into your studies or publications.
- Investors: Evaluate your investment strategies and analyze valuation metrics for Viracta Therapeutics, Inc. (VIRX).
- Market Analysts: Enhance your analysis with a tailored, user-friendly DCF model specific to biotech companies.
- Healthcare Entrepreneurs: Understand how public biotech firms like Viracta Therapeutics, Inc. (VIRX) are assessed in the market.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Viracta Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Viracta Therapeutics, Inc. (VIRX).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.